Q3 2023 Results - Reimagining Medicine

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology sabatolimab - TIM3 antagonist Conclusions NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 Indication Phase Patients 86 Primary Outcome Measures Arms Intervention Target Patients Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy Readout Milestone(s) 2023 Publication TBD 74 Investor Relations | Q3 2023 Results Appendix Innovation: Clinical trials Neuroscience Oncology sabatolimab - TIM3 antagonist NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Indication Phase Myelodysplastic syndrome Phase 3 Patients 500 Primary Overall survival Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Publication TBD References Abbreviations Other Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) 2024 NOVARTIS | Reimagining Medicine

View entire presentation